Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.82), $0.08 worse than the analyst estimate of ($1.74). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $18.3 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)